|Company name||Alexion Pharmaceuticals, Inc.|
|Live stock price||[stckqut]ALXN[/stckqut]|
|P/E compared to competitors||Fair|
|Confident Investor Rating||Good|
|Target stock price (TWCA growth scenario)||$154.89|
|Target stock price (averages with growth)||$200.16|
|Target stock price (averages with no growth)||$125.48|
|Target stock price (manual assumptions)||$154.26|
The following company description is from Google Finance: http://www.google.com/finance?q=alxn
Alexion Pharmaceuticals, Inc. (Alexion) is a biopharmaceutical company focused on serving patients with severe and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products. Its marketed product Soliris (eculizumab) is the first and only therapeutic approved for patients with two ultra-rare and severe disorders resulting from chronic uncontrolled activation of the complement component of the immune system: paroxysmal nocturnal hemoglobinuria (PNH), an ultra-rare and life-threatening blood disorder, and atypical hemolytic uremic syndrome (aHUS), an ultra-rare and life-threatening genetic disease. On February 7, 2012, it acquired Enobia Pharma Corp. (Enobia). On February 8, 2011, it acquired patents and assets from Orphatec Pharmaceuticals GmbH (Orphatec). On January 28, 2011, it acquired Taligen Therapeutics, Inc. (Taligen). It acquired Asfotase alfa in February 2012.
Confident Investor comments: At this price and at this time, I think that a Confident Investor can confidently invest in this stock.
If you would like to understand how to evaluate companies like I do on this site, please read my book, The Confident Investor.